Voices
Raffaele Colombo: Sad to See yet Another Ideal ADC Study Terminated
Raffaele Colombo/zymeworks.com

Raffaele Colombo: Sad to See yet Another Ideal ADC Study Terminated

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:

“Sad to see yet another ideal (on paper) ADC terminated, per clinicaltrials.gov.

MYTX-011:

  • validated cMet target + MMAE payload
  • pH-dependent mAb
  • site-specific homogenous DAR2
  • stable linker

A good reminder that improved stability and design alone ≠ clinical success!”

ADC

More posts featuring Raffaele Colombo on OncoDaily.

ADC cancer OncoDaily Oncology Raffaele Colombo